The FDA approved PI 3K inhibitor GDC ‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma-Reference-Cited by-同舟云学术

The FDA approved PI 3K inhibitor GDC ‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma

Published:2018-01-29 Issue:4 Volume:22 Page:2153-2161
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Ehrhardt Michael¹,Craveiro Rogerio B.¹^ORCID,Velz Julia¹,Olschewski Martin¹,Casati Anna¹,Schönberger Stefan¹^ORCID,Pietsch Torsten²,Dilloo Dagmar¹

Affiliation:

1. Department of Pediatric Hematology and Oncology Center for Pediatrics University of Bonn Medical Center Bonn Germany

2. Department of Neuropathology University of Bonn Bonn Germany

Funder

Caroline Wenzel Foundation

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.13489

Reference53 articles.

1. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

2. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors

3. c-kit Expression and Mutational Analysis in Medulloblastoma

4. KIT expression and methylation in medulloblastoma and PNET cell lines and tumors

5. PDGFRB is overexpressed in metastatic medulloblastoma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16

2. The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro;Journal of Cellular and Molecular Medicine;2022-11-15

3. Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy;Cellular Signalling;2022-11

4. STAT3 in medulloblastoma: a key transcriptional regulator and potential therapeutic target;Molecular Biology Reports;2022-06-18

5. Targeting Angiogenic Factors for the Treatment of Medulloblastoma;Current Treatment Options in Oncology;2022-04-12